SEC Tracker
Get the app
RCEL · XBRL financial data

AVITA Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue13,64514,195*11,10415,19519,54618,406*18,51418,41817,06217,615*19,25121,702
Cost of revenue2,1131,796*1,5132,1113,1902,280*2,8333,4693,1873,304*3,5233,935
Gross profit11,53212,399*9,59113,08416,35616,126*15,68114,94913,87514,311*15,72817,767
Research and development4,3946,765*5,1944,8875,4284,850*6,2845,1173,7485,691*5,6295,078
General and administrative6,1247,750*8,9637,5199,5907,124*6,3906,6667,2277,090*6,0615,971
Total operating expenses21,05024,731*26,79728,70830,16226,083*27,50826,09723,02824,719*24,53124,622
Other operating income (expense)21259*——————————
Operating income (loss)(9,306)(12,273)*(17,206)(15,624)(13,806)(9,957)*(11,827)(11,148)(9,153)(10,408)*(8,803)(6,855)
Interest expense101,122*1,3561,3471,3591,298*1,2331,2521,2681,250*1,4241,463
Other income (expense)6156,342*(66)1,611(1,068)(315)*(791)2,484(2,751)20*(395)688
Income tax expense (benefit)1112*3033(28)19*8415(17)*(11)33
Net income (loss)(8,712)(7,065)*(18,658)(15,393)(16,205)(11,589)*(13,859)(9,920)(13,187)(11,621)*(10,611)(7,663)
Earnings per share, basic USD per share0.34—(0.73)(0.60)(0.62)(0.44)*(0.53)(0.38)(0.46)(0.38)*(0.35)(0.25)
Earnings per share, diluted USD per share0.34—(0.73)(0.60)(0.62)(0.44)*(0.53)(0.38)(0.46)(0.38)*(0.35)(0.25)
Weighted average shares, basic thousands of shares25,40225,478*25,63825,76025,98426,146*26,25426,36828,39330,377*30,54130,750
Weighted average shares, diluted thousands of shares25,40225,478*25,63825,76025,98426,146*26,25426,36828,39330,377*30,54130,750

Balance sheet

CSV

Fiscal quarters (RCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents50,85422,11816,95117,45218,63914,05014,87012,21615,42210,2438,3099,139
Marketable securities9,26466,93951,23236,60425,76621,83510,9483,4747,8917,9425,9521,996
Accounts receivable5,8757,6647,0818,71710,28811,78612,04511,3439,0139,0869,8859,867
Inventory4,3775,5967,1716,7096,2297,2698,3957,5367,2406,9266,1175,287
Prepaid and other current assets3,3561,6593,5233,3822,8922,0041,7091,6841,8011,2931,3842,105
Total current assets73,927104,00685,98672,95863,92557,00047,96736,25341,36735,49031,64728,394
Property and equipment, net1,8621,8774,2977,0249,15110,0189,8949,6899,8848,6308,2117,678
Right-of-use asset2,6072,4403,2753,9383,7803,5713,3563,1323,1282,8992,6662,655
Total assets81,014111,64097,38187,82681,05179,71169,55658,13463,72856,39251,54447,777
Current portion of long-term debt—————0——42,44942,98446,13946,659
Total current liabilities11,83613,19911,86213,78717,14120,15822,95662,60261,83162,67766,67168,714
Long-term debt—39,81241,30140,98942,54742,24541,46442,21600——
Lease liability, non-current1,8451,7022,5323,2813,0792,8402,6092,3722,3242,1351,9811,822
Total liabilities17,40761,89163,98563,51368,60074,96874,06370,98170,39473,04274,71075,615
Accumulated deficit(290,904)(297,969)(316,627)(332,020)(348,225)(359,814)(373,673)(383,593)(396,780)(408,401)(419,012)(426,675)
Total stockholders' equity62,97849,05632,56923,91512,2274,499(4,571)(12,892)(6,666)(16,650)(23,166)(27,838)
Total liabilities and equity81,014111,64097,38187,82681,05179,71169,55658,13463,72856,39251,54447,777
Common shares outstanding (cover page) thousands of shares25,55125,70725,80025,99026,21826,35826,43526,61930,49330,63230,77730,927

Cash flows

CSV

Fiscal quarters (RCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(8,712)(7,065)*(18,658)(15,393)(16,205)(11,589)*(13,859)(9,920)(13,187)(11,621)*(10,611)(7,663)
Stock-based compensation2,430*2,171*2,5914,027*4,080*2,798*2,6942,675*2,777*1,373*1,1011,988*
Depreciation and amortization164*187*203204*310*409*521552*574*700*627605*
Net cash from operating activities(8,974)*(10,863)*(20,864)(12,780)*(7,214)*(8,081)*(10,309)(10,229)*(5,219)*(5,438)*(10,072)(3,496)*
Purchases of property and equipment502*296*1,1472,652*3,760*1,612*221524*934*(674)*19108*
Net cash from investing activities21,761*(57,304)*15,06612,432*7,394*2,471*10,7667,016*(5,341)*11*2,0413,889*
Proceeds from issuing common stock—————————0*——
Proceeds from long-term debt—year only——————————
Net cash from financing activities600*39,432*631849*1,007*1,021*363559*13,766*248*6,097437*
Net change in cash13,369*(28,736)*(5,167)501*1,187*(4,589)*820(2,654)*3,206*(5,179)*(1,934)830*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
AVITA Medical9,13921,702(3,496)*30.9M3.2 quarters 10-QJun 30, 2026
Lakeland Industries17,90150,139(404)*9.9M— 10-QJul 31, 2026
Picard Medical382,954(1,352)*2.3M0.0 quarters 10-QJun 30, 2026
Anika Therapeutics38,41232,610(684)*13.4M56.2 quarters 10-QJun 30, 2026
Sanara MedTech15,42128,1372,038*9.2M— 10-QJun 30, 2026
Neuronetics22,10641,962not reported77.7M— 10-QSep 30, 2026
Stereotaxis10,4917,670(3,675)*100.2M2.9 quarters 10-QJun 30, 2026
Profound Medical38,2712,483(11,338)*36.5M3.4 quarters 10-QJun 30, 2026
Sight Sciences79,75323,388(5,663)*55.1M14.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.